Klebsiella Species

Most healthy adults carry small amounts of Klebsiella in their gut without ever knowing it. The trouble starts when these bacteria expand beyond a quiet background population and begin to dominate. At that point, your gut becomes a reservoir for organisms that can cause pneumonia, urinary tract infections, liver abscess, and bloodstream infections, particularly if your immune system or gut barrier is later stressed.

Stool testing for Klebsiella gives you a direct look at how much of this opportunist is living in your intestine right now. It is a research-stage measurement without standardized clinical cutpoints, but it is useful for spotting overgrowth patterns that standard blood panels and routine stool cultures will not catch.

What This Test Is Actually Measuring

Klebsiella is a genus of Gram-negative, encapsulated, rod-shaped bacteria in the Enterobacteriaceae family. The genus includes several species, with K. pneumoniae the most clinically important, followed by K. oxytoca, K. variicola, K. quasipneumoniae, K. aerogenes, and K. michiganensis. They live in the nose, throat, skin, and intestinal tract of healthy people, but they are also among the most common causes of opportunistic hospital and community infections worldwide.

This test quantifies the colony-forming units (CFU) of Klebsiella in your stool. The result tells you how heavily your colon is colonized, which is a different question from whether you are currently infected. Carriage is common: in one cross-sectional study of nearly 3,000 adults from a general population, 16.3% had detectable gastrointestinal Klebsiella pneumoniae. In a Taiwanese community sample of 204 adults, intestinal carriage reached 63%.

Gut Overgrowth and Infection Risk

The single most actionable finding in the human research is that high relative abundance of Klebsiella in the gut predicts later infection. Among 238 colonized hospitalized patients, those whose stool was more than 22% Klebsiella by qPCR had roughly 2.9 times the odds of developing any Klebsiella infection and about 4.1 times the odds of bloodstream infection compared with patients below that threshold.

A separate prospective study in long-term acute care admissions found that patients whose gut microbiota was at least 22% carbapenem-resistant Klebsiella pneumoniae carbapenemase (KPC) producers had about four times the rate of bloodstream infection from that same organism compared with those below the cutoff. These findings come from sick, hospitalized populations, not from asymptomatic community adults, but they establish that the gut acts as a launchpad: when Klebsiella crowds out normal bacteria, the chance that it crosses into the bloodstream goes up.

Cholangiocarcinoma and Gut-Bile Signaling

Klebsiella is enriched in both the gut and bile of people with cholangiocarcinoma (a cancer of the bile ducts). Research has proposed a Bifidobacterium-to-Klebsiella ratio as a non-invasive marker: the ratio falls as cancer progresses and as the tumor marker CA19-9 rises. In a study of 58 participants, combining this stool ratio with serum CA19-9 produced very strong discrimination for cholangiocarcinoma. The takeaway is that a relative shift toward Klebsiella, rather than an absolute number on its own, may carry meaning for hepatobiliary risk.

Diabetic Kidney Disease

In 45 people with diabetic kidney disease, higher circulating DNA from K. oxytoca tracked with higher creatinine and blood urea nitrogen and lower estimated glomerular filtration rate (a measure of how well your kidneys filter blood). The bacteria appeared to be translocating from a leaky gut into the bloodstream as kidney function deteriorated. The study did not measure stool Klebsiella directly, but it suggests that gut Klebsiella expansion can have downstream consequences far beyond the colon.

Inflammatory Bowel Disease and Gut Inflammation

Altered Klebsiella populations are part of the gut microbial signature seen in Crohn's disease and other inflammatory states. In a tissue colonization study of 274 IBD samples, K. pneumoniae was among the bacteria linked to disease phenotype. People who carry inflammatory bowel disease, take proton pump inhibitors, or use NSAIDs regularly tend to have higher gastrointestinal Klebsiella carriage rates.

Sepsis Prognosis

In 109 septic patients followed during ICU admission, higher gut Klebsiella abundance was part of a microbial and metabolite signature that helped predict mortality. While this is a hospital finding rather than a screening one, it reinforces the broader pattern: when Klebsiella dominates the gut, outcomes tend to be worse.

Why a Single Reading Is Not Enough

Stool microbiome composition shifts with diet, recent antibiotics, illness, and travel. A single stool sample is a snapshot, and a low or normal-seeming Klebsiella reading on one day does not rule out a future bloom, especially if you are about to start a high-risk medication or hospital admission. Tracking your trend matters more than reacting to any one number.

A reasonable cadence for a proactive adult: get a baseline, retest 3 to 6 months later if you are making meaningful gut-related changes (stopping a long-term PPI, finishing a course of antibiotics, treating a digestive condition), then at least annually thereafter. Trend direction and consistency carry more weight than any individual cutpoint, particularly because there is no universally agreed CFU number that defines pathological overgrowth in stool.

Reference Ranges

There is no consensus clinical cutpoint for stool Klebsiella in CFU/g for asymptomatic adults. The closest research-based threshold is from a study of 238 hospitalized colonized patients that used qPCR to define high colonization as more than 22% of total fecal bacteria. That is a relative abundance threshold, not a direct CFU/g equivalent, and it was derived from a sick inpatient population rather than community adults. Your lab will report its own reference range based on its assay platform.

Source: derived from research thresholds reported by Sun et al. 2021 and Shimasaki et al. 2018. Compare your results within the same lab over time for the most meaningful trend, since assays and units differ across providers.

When Results Can Be Misleading

• Recent antibiotics: Broad-spectrum antibiotics can either temporarily raise Klebsiella by wiping out competitors or temporarily suppress it. In a randomized trial of 227 infants, courses such as amoxicillin plus cefotaxime caused major shifts in gut Klebsiella that took up to 12 months to fully normalize.
• Acute illness or hospitalization: Critical illness, surgery, and chemotherapy all destabilize the gut microbiome over days to weeks, sometimes producing dramatic Klebsiella blooms unrelated to your baseline state.
• Sample timing and handling: Stool composition varies between bowel movements and degrades if not preserved correctly. Submitting a sample that does not represent your typical gut state, or that sat too long before reaching the lab, can shift apparent abundance.
• Species misidentification: Routine identification methods often label K. variicola and K. quasipneumoniae as K. pneumoniae. In one bloodstream infection cohort, about 18% were actually K. variicola and 9% K. quasipneumoniae rather than the reported K. pneumoniae.

What to Do With an Elevated Result

An elevated stool Klebsiella alone is not a diagnosis. It is a signal worth investigating, especially if you have other markers of gut dysbiosis (low Bifidobacterium, low Faecalibacterium prausnitzii, high calprotectin), are about to undergo surgery, are immunocompromised, or are managing inflammatory bowel disease, diabetic kidney disease, or hepatobiliary symptoms. The right next steps are usually a broader gut microbiome panel, a review of medications that can drive Klebsiella up (PPIs, metformin, NSAIDs, antipsychotics), and a conversation with a gastroenterologist or infectious disease specialist if levels are very high or paired with symptoms.